Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iPSF
- Development stage
- Preclinical
- Lead developer
- I Peace
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular, Intravenous, Topical
01
Overview
iPSF is a cell-free research compound and secretome-derived product developed by I Peace, Inc. and Reju, Inc. It is obtained by isolating and purifying bioactive factors, such as growth factors and signaling molecules, from the culture supernatant of induced pluripotent stem cell (iPSC)-derived cells, without containing any living cells. iPSF is being investigated for its potential applications in healthy longevity, cellular rejuvenation, and tissue regeneration, with research observing changes in extracellular matrix production and aging-associated biomarkers. It is also being explored in partnership with Kosé for personalized beauty and skincare formulations.
- Other names
- iPS cell extractiPS cell-derived factorsiPSC-derived factors
Beyond the preview
Go deeper on iPSF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iPSF.